Elektif Perkütan Koroner Girişim Sonrası Minör Miyokardiyal Hasar Gelişen Hastalarda Nötrofil/Lenfosit Oranının Değerlendirilmesi

Amaç: Bu çalışmada elektif perkütan koroner girişim (PKG) geçiren hastalarda nötrofil/lenfositoranı (NLO) ve minör miyokardiyal hasar (MMH) arasındaki korelasyonu değerlendirmek amaçlanmıştır.Gereç ve Yöntemler: MMH varlığına göre çalışma popülasyonu iki gruba ayrıldı: MMH (+) grup(n=77) ve MMH (-) grup (n=86). Kardiyak troponin I (cTnI) ve CK-MB prosedürden önce ve işlemden 12 saat sonra ölçüldü. cTnI’nin 0,06 ng/ml’den yüksek olması MMH olarak kabul edildi. Beyazkan hücresi sayımı ve periferik diferansiyel sayımları işlemden sonra ölçüldü. NLO mutlak nötrofilve lenfosit sayıları oranlanarak hesaplandı.Bulgular: Hastalar çoğunlukla erkek (%62) ve ortalama yaş 60 idi. MMH’li hastalarda ortalamaNLO’nun daha yüksek olduğu görüldü (MMH’li grupta 5,0 iken MMH’siz grupta 3,6; p=0,003).MMH’li grupta erkek ve hipertansif hasta sayısı daha fazla idi. İşlemden sonra tüm hastalar hesaplanan NLO tertillerine göre de gruplandırıldı. Daha yüksek tertillerdeki hastalarda MMH dahafazla idi. Çok değişkenli analizde NLO, erkek cinsiyet, tip-C lezyon MMH’nin bağımsız belirleyicileri olarak tespit edildi.Tartışma ve Sonuç: Çalışmamız NLO’nun elektif PKG sonrası MMH gelişen hastalarda daha yüksek olduğunu göstermektedir.

An Assessment of the Neutrophil/Lymphocyte Ratio in Patients Developing Minor Myocardial Injury Following Elective Percutaneous Coronary Intervention

Aim: In this study, we aimed to evaluate the correlation between the neutrophil/lymphocyte ratio (NLR) and minor myocardial injury (MMI) in patients who underwent elective percutaneous coronary intervention (PCI). Materials and Methods: According to MMI presence, the study population was divided into two groups: the MMI (+) group (n=77) and the MMI (-) group (n=86). Cardiac troponin I (cTnI) and CK-MB were measured before and 12 hours after the procedure. A level of cTnI higher than 0.06 ng/ml was considered MMI. White blood cell counts and peripheral differential counts were measured after the procedure. The NLR was calculated as the ratio between the absolute neutrophil and lymphocyte counts. Results: Patients were mostly male (62%) with a mean age of 60 years. The patients with MMI were found to have a higher mean NLR (5.0 in the MMI [+] group vs 3.6 in the MMI [-] group, p=0.003). The MMI (+) group included more male and hypertensive patients. After the procedure all patients were also grouped according to the NLR tertiles determined. The higher-tertile patients had a higher MMI prevalence. In the multivariate analysis, NLR, male sex, and type-C lesion were independent predictors of MMI. Discussion and Conclusion: Our study shows that patients developing MMI following elective PCI exhibit higher NLRs.

PDF

___

1. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, ve ark. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241– 51.
2. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q-wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol. 1991;17:621–6.
3. Oh JK, Shub C, Ilstrup DM, Reeder GS. Creatine kinase release after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1985;109:1225–31.
4. Simoons ML, van den Brand M, Lincoff M, Harrington R, van der Wieken R, Vahanian A, ve ark. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J. 1999;20:1112–9.
5. Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR Jr, Rihal CS. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol. 2006;48:1765– 70.
6. Nallamothu BK, Chetcuti S, Mukherjee D, Grossman PM, Kline-Rogers E, Werns SW, ve ark. Prognostic implication of troponin I elevation after percutaneous coronary intervention. Am J Cardiol. 2003;91:1272–74.
7. Gómez JA, Cequier A, Valero J, González-Costello J, Mañas P, Iràculis E, ve ark. Minor myocardial damage during percutaneous coronary intervention does not affect long-term prognosis. Rev Esp Cardiol. 2009;62:625–32.
8. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–26.
9. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, ve ark. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45:1638–43.
10. Guasti L, Dentali F, Castiglioni L, Maroni L, Marino F, Squizzato A, ve ark. Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularisation. A systematic review on more than 34,000 subjects. Thromb Haemost. 2011;106:591–9.
11. Benites-Zapata VA, Hernandez AV, Nagarajan V, Cauthen CA, Starling RC, Tang WH. Usefulness of neutrophil-to-lymphocyte ratio in risk stratification of patients with advanced heart failure. Am J Cardiol. 2015;115:57– 61.
12. Cho KH, Jeong MH, Ahmed K, Hachinohe D, Choi HS, Chang SY, ve ark. Value of early risk stratification using hemoglobin level and neutrophil-to-lymphocyte ratio in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2011;107:849–56.
13. Han YC, Yang TH, Kim DI, Jin HY, Chung SR, Seo JS, ve ark. Neutrophil to lymphocyte ratio predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Korean Circ J. 2013;43:93–9.
14. Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta. 2008;395:27e31.
15. Cho KI, Ann SH, Singh GB, Her AY, Shin ES. Combined usefulness of the platelet-to-lymphocyte ratio and the neutrophil-to-lymphocyte ratio in predicting the longterm adverse events in patients who have undergone percutaneous coronary intervention with a drug-eluting stent. PLoS One. 2015;10:e0133934.
16. Kruk M, Przyluski J, Kalinczuk L, Pregowski J, Deptuch T, Kadziela J, ve ark. Association of non-specific inflammatory activation with early mortality in patients with ST-elevation acute coronary syndrome treated with primary angioplasty. Circ J. 2008;72:205e211.
17. Bekler A, Erbag G, Sen H, Gazi E, Ozcan S. Predictive value of elevated neutrophil-lymphocyte ratio for left ventricular systolic dysfunction in patients with non ST-elevated acute coronary syndrome. Pak J Med Sci. 2015;31:159–63.
18. Yaylak B, Ede H, Baysal E, Altıntas B, Akyuz S, Sevuk U, ve ark. Neutrophil/lymphocyte ratio is associated with right ventricular dysfunction in patients with acute inferior ST-segment elevation myocardial infarction. Cardiol J. 2016;23:100–106.
19. Duffy BK, Gurm HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2006;97:993–6.
20. Arıkan R. Araştırma Teknikleri ve Rapor Hazırlama. Ankara: Asil Yayın; 2004.
21. Yu S, Arima H, Bertmar C, Clarke S, Herkes G, Krause M. Neutrophil to lymphocyte ratio and early clinical outcomes in patients with acute ischemic stroke. J Neurol Sci. 2018;387:115–18.
22. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, ve ark. Creactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20.
23. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, ve ark. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.
24. Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol. 1998;32:35–41.
25. Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, ve ark. Impact of preprocedural white blood cell count on long-term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. Heart. 2003;89:1200–4.
26. Park JJ, Jang HJ, Oh IY, Yoon CH, Suh JW, Cho YS, ve ark. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013;111:636–42.
27. Pan W, Zhao D, Zhang C, Li W, Yu J, Wang S, ve ark. Application of neutrophil/lymphocyte ratio in predicting coronary blood flow and mortality in patients with STelevation myocardial infarction undergoing percutaneous coronary intervention. J Cardiol. 2015;66:9–14.
28. Poludasu S, Cavusoglu E, Khan W, Marmur JD. Neutrophil to lymphocyte ratio as a predictor of long-term mortality in African Americans undergoing percutaneous coronary intervention. Clin Cardiol. 2009;32:E6– E10.
29. Mangiacapra F, Barbato E. Clinical implications of platelet-vessel interaction. J Cardiovasc Transl Res. 2013;6:310–5.
30. Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation. 2013;128:1910e1923.
31. Onsrud M, Thorsby E. Influence of in vivo hydrocortisone on some human blood lymphocyte subpopulations. I. Effect on natural killer cell activity. Scand J Immunol. 1981;13:573e579.
32. Bressi E, Mangiacapra F, Ricottini E, Cavallari I, Colaiori I, Di Gioia G, ve ark. Relation of neutrophil to lymphocyte ratio with periprocedural myocardial damage in patients undergoing elective percutaneous coronary intervention. Am J Cardiol. 2016;118:980–4.